Get started
Work

LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Year: 2020
Type: conference-abstract
DOI: 10.1016/j.annonc.2020.08.2261
Authors: K.N. Moore, M. Bookman, J. Sehouli, A. Miller, C. Anderson, G. Scambia, T. Myers, C. Taskiran, K. Robison, J. Maenpaa, L.J. Willmott, N. Colombo, J. Thomes-Pepin, M.A. Gold, C. Aghajanian, F. Wu, L. Molinero, V. Khor, Y.G. Lin, S. Pignata
Institutions: OU Health Stephenson Cancer Center, University of Oklahoma, Kaiser Permanente Northern California, Charité - Universitätsmedizin Berlin, Roswell Park Comprehensive Cancer Center, Willamette Valley Cancer Institute and Research Center, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Baystate Medical Center, Baystate Health, Koç University, Amerikan Hastanesi, Women & Infants Hospital of Rhode Island, Tampere University, Tampere University Hospital, Arizona Oncology, European Institute of Oncology, University of Milano-Bicocca, Minnesota Oncology, Oklahoma Cancer Specialists and Research Institute, Weill Cornell Medicine, Genentech, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3089223695
Cites:
Cited by: 36
Related to: 10